New acid blocker takes on standard drug for Post-Surgery reflux
NCT ID NCT06955520
First seen Apr 30, 2026 · Last updated Jun 23, 2026 · Updated 8 times
Summary
This study tests whether a newer acid-reducing drug, Vonaprazan, heals acid reflux better than the standard drug Esomeprazole in people who had POEM surgery for achalasia. About 300 adults with moderate to severe esophagitis will take one of the two drugs for 8 weeks. The goal is to see which drug heals the esophagus more effectively and improves symptoms like heartburn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asian Institute of Gastroenterology /Aig Hospitals
RECRUITINGHyderabad, Telangana, 500082, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vonaprazan (a potassium-competitive acid blocker) and Esomeprazole (a proton pump inhibitor)
What this could lead to
If Vonaprazan works better, it could offer a more effective way to heal acid reflux after POEM surgery, reducing symptoms and the need for stronger treatments.
What could go wrong
This is a relatively small, early-stage comparison. Vonaprazan may not prove significantly better than the standard drug, and results may not apply to all GERD patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.